B-CELL LYMPHOMA
Clinical trials for B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at tough childhood cancers
Disease control CompletedThis early-phase trial tested whether a new type of immune cell therapy (CD22 CAR T cells) could be safely made and given to 10 children and young adults whose B-cell leukemia or lymphoma had come back or stopped responding to treatment. The therapy uses the patient's own immune …
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Kara Lynn Davis • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis study tested an oral drug called LOXO-305 (pirtobrutinib) in 803 people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other non-Hodgkin lymphomas whose cancer had stopped responding to or could not tolerate standard treatments. The goal was to find the be…
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated Jun 08, 2026 13:12 UTC
-
CRISPR-Engineered immune cells take on tough blood cancers
Disease control CompletedThis study tested a new treatment called CTX131 for adults with blood cancers that came back or didn't respond to other therapies. CTX131 uses CRISPR gene editing to create donor immune cells that target and attack cancer cells. The goal was to see if it's safe and works, but it'…
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics • Aim: Disease control
Last updated Jun 08, 2026 13:06 UTC
-
New drug candidate BR101801 tested in patients with advanced blood cancers
Disease control CompletedThis early-phase trial tested a new drug called BR101801 in 26 adults with advanced blood cancers like lymphoma and leukemia that had not responded to other treatments. The main goals were to find a safe dose and check for side effects. The study was completed, but results are no…
Matched conditions: B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Disease control
Last updated May 26, 2026 12:01 UTC